The aim of the Translational Informatics (Tl) core is to provide the Informatics infrastructure, and to develop, deploy and maintain data systems and applications that optimize the translation of basic scientific discoveries into clinical applications. Tl members are made up of experienced informaticians and clinical research support specialists and analysts with backgrounds in clinical data coordination, biomedical research, molecular biology, computer science, software engineering, and application architecture. The Tl core develops data systems that span a range of users, from individual investigators, to individual programs within the Cancer Center, and to the Cancer Center as a whole. Tl works with researchers, other Cores, and Cancer Center administration to fulfill its goals with the ability to provide customizable informatics solutions for all data needs. Over the next five years, Tl will continue to provide the Cancer Center members with Informatics and computational support for an array of activities, including continued participation in grant applications and expanding efforts as needed to respond to changing needs of funded grants. Tl priorities are to: 1) Access, training, and management of Clinical and Biomedical Software Tools 2) Provide access to Clinical and Biomedical Data for Research 3) Research Data Management Solutions including access to High Performance Compute Cluster and allocated software. Pathway analysis tools (IPA), and design of Data Collection Models 4) Biospecimen Data Management 5) Custom Research Software Development including user interfaces 6) Oversee and provide guidance for Research Data Privacy, Security, and Quality Control 7) Standardize and Harmonize Data Collection Vocabularies and Common Data Elements 8) Maintenance of databases. Patient centric data-warehouse, and associated web sites 9) Custom data services involving specific programming expertise for specialized databases

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
San Francisco
United States
Zip Code
John, Constance M; Phillips, Nancy J; Din, Richard et al. (2016) Lipooligosaccharide Structures of Invasive and Carrier Isolates of Neisseria meningitidis Are Correlated with Pathogenicity and Carriage. J Biol Chem 291:3224-38
Shatsky, Maxim; Dong, Ming; Liu, Haichuan et al. (2016) Quantitative Tagless Copurification: A Method to Validate and Identify Protein-Protein Interactions. Mol Cell Proteomics 15:2186-202
Nordström, Tobias; Van Blarigan, Erin L; Ngo, Vy et al. (2016) Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer. Prostate 76:339-48
Bulut-Karslioglu, Aydan; Biechele, Steffen; Jin, Hu et al. (2016) Inhibition of mTOR induces a paused pluripotent state. Nature 540:119-123
Akutagawa, J; Huang, T Q; Epstein, I et al. (2016) Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras. Leukemia 30:1335-43
Baeza-Raja, Bernat; Sachs, Benjamin D; Li, Pingping et al. (2016) p75 Neurotrophin Receptor Regulates Energy Balance in Obesity. Cell Rep 14:255-68
Ko, Andrew H; Bekaii-Saab, Tanios; Van Ziffle, Jessica et al. (2016) A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Clin Cancer Res 22:61-8
Nosbaum, Audrey; Prevel, Nicolas; Truong, Hong-An et al. (2016) Cutting Edge: Regulatory T Cells Facilitate Cutaneous Wound Healing. J Immunol 196:2010-4
Phan, An T; Fernandez, Samantha G; Somberg, Jessica J et al. (2016) Epstein-Barr virus latency type and spontaneous reactivation predict lytic induction levels. Biochem Biophys Res Commun 474:71-5
Chang, Matthew T; Asthana, Saurabh; Gao, Sizhi Paul et al. (2016) Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol 34:155-63

Showing the most recent 10 out of 135 publications